Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Myeloid, Acute 15Myelodysplastic Syndromes 10Recurrence 7Ovarian Neoplasms 7Multiple Myeloma 7Pancreatic Neoplasms 6Lymphoma 6Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Colorectal Neoplasms 5Burkitt Lymphoma 5Stomach Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma 3Osteosarcoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Biphenotypic, Acute 3Leukemia, B-Cell 3Leukemia 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 2Triple Negative Breast Neoplasms 2Thymoma 2

Interventions

remdesivir 1fludarabine 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Methods 1Interviews as Topic 1Educational Status 1Early Intervention, Educational 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Autoimmune Diseases × fludarabine × 30 days × Clear all
NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡